325 related articles for article (PubMed ID: 27608846)
1. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
2. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Proia DA; Smith DL; Zhang J; Jimenez JP; Sang J; Ogawa LS; Sequeira M; Acquaviva J; He S; Zhang C; Khazak V; Astsaturov I; Inoue T; Tatsuta N; Osman S; Bates RC; Chimmanamada D; Ying W
Mol Cancer Ther; 2015 Nov; 14(11):2422-32. PubMed ID: 26271675
[TBL] [Abstract][Full Text] [Related]
3. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
Gaponova AV; Nikonova AS; Deneka A; Kopp MC; Kudinov AE; Skobeleva N; Khazak V; Ogawa LS; Cai KQ; Duncan KE; Duncan JS; Egleston BL; Proia DA; Boumber Y; Golemis EA
Clin Cancer Res; 2016 Oct; 22(20):5120-5129. PubMed ID: 27267850
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
5. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
Deneka AY; Haber L; Kopp MC; Gaponova AV; Nikonova AS; Golemis EA
PLoS One; 2017; 12(4):e0176747. PubMed ID: 28453558
[TBL] [Abstract][Full Text] [Related]
7. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Cosetti M; Wexler LH; Calleja E; Trippett T; LaQuaglia M; Huvos AG; Gerald W; Healey JH; Meyers PA; Gorlick R
J Pediatr Hematol Oncol; 2002 Feb; 24(2):101-5. PubMed ID: 11990694
[TBL] [Abstract][Full Text] [Related]
9. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
11. Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.
Schöffski P; Wang CC; Schöffski MP; Wozniak A
Oncol Res Treat; 2024; 47(1-2):18-41. PubMed ID: 38016427
[TBL] [Abstract][Full Text] [Related]
12. BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.
Ambati SR; Shieh JH; Pera B; Lopes EC; Chaudhry A; Wong EW; Saxena A; Su TL; Moore MA
Oncotarget; 2016 Jul; 7(28):43062-43075. PubMed ID: 27248664
[TBL] [Abstract][Full Text] [Related]
13. Prospective use of the single-mouse experimental design for the evaluation of PLX038A.
Ghilu S; Li Q; Fontaine SD; Santi DV; Kurmasheva RT; Zheng S; Houghton PJ
Cancer Chemother Pharmacol; 2020 Feb; 85(2):251-263. PubMed ID: 31927611
[TBL] [Abstract][Full Text] [Related]
14. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Numbenjapon T; Wang J; Colcher D; Schluep T; Davis ME; Duringer J; Kretzner L; Yen Y; Forman SJ; Raubitschek A
Clin Cancer Res; 2009 Jul; 15(13):4365-73. PubMed ID: 19549776
[TBL] [Abstract][Full Text] [Related]
15. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Riccardi A; Meco D; Ubezio P; Mazzarella G; Marabese M; Faircloth GT; Jimeno J; D'Incalci M; Riccardi R
Anticancer Drugs; 2005 Sep; 16(8):811-5. PubMed ID: 16096428
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
19. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
20. The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Cassinelli G; Zuco V; Petrangolini G; De Cesare M; Tortoreto M; Lanzi C; Cominetti D; Zaffaroni N; Orlandi A; Passeri D; Meco D; Di Francesco AM; Riccardi R; Bucci F; Pisano C; Zunino F
Biochem Pharmacol; 2012 Jul; 84(2):163-71. PubMed ID: 22525722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
